Developer docs
API playgroundTry for free, no card

Search company profiles

Outcome Capital

Full company profile

uuid0007avo

Namestring
Outcome Capital
Legal namestring
Outcome Capital, LLC
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Outcome Capital, LLC is a privately held investment banking and strategic advisory firm headquartered in Boston, Massachusetts, with a secondary office in Charlotte, North Carolina. Founded around 1998-2000 and registered with the SEC as a broker-dealer and FINRA/SIPC member, the firm operates as an affiliate of Outcome Holdings, LLC and focuses exclusively on middle-market growth companies in the life sciences and healthcare sectors, spanning biotech, diagnostics, medical devices, pharmaceuticals, healthcare IT, digital health, pharma services, and healthcare services. Its service platform combines investment banking (M&A advisory, capital raising, value creation, value realization) with strategic and financial advisory, delivered through dedicated industry practices and supported by content such as the Life Sciences Pulse monthly newsletter.

The firm differentiates itself through a scientist-banker model: most Managing Directors and Vice Presidents hold PhDs or CFA credentials with prior operating roles at major pharmaceutical and medical device companies including Novartis, Pfizer, Bayer, Johnson & Johnson, Schering-Plough, and Becton-Dickinson. Notable closed transactions include the $175M Propella Therapeutics acquisition by Astellas Pharma, the $120M GenePOC acquisition by Meridian Bioscience, a $32M Elios Vision growth equity financing, the ZIEN Medical/Averra Holdings merger, and the RealizedCare/XRHealth acquisition, among others spanning 2016-2025.

Outcome Capital earns revenue primarily through success fees paid by issuers upon closing of M&A and capital raising mandates, supplemented by fees from private placement of securities to qualified institutional investors. Pricing is not publicly disclosed; fee percentages are pre-determined per engagement and vary by transaction. The firm has no productized software, AI/ML, or technology platform; its offering is advisory labor and relationship-based deal execution, with recent expansion in 2025-2026 via the Healthcare Services Practice, the Pharmacy and Related Services Advisory Board, and an ophthalmology practice led by a new senior hire.

Short descriptiontext

Outcome Capital is a privately held Boston-based investment banking and strategic advisory firm serving middle-market growth companies in life sciences and healthcare, providing M&A advisory, capital raising, and strategic advisory through a scientist-banker team with PhD-trained Managing Directors and Big Pharma operating experience.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences investment banking, healthcare strategic advisory, mergers and acquisitions advisory, capital raising services, middle market advisory
Industry5 codes
PRIMARYBPAHADAB
Corporate Finance & Capital Advisory
SECONDARYBPAHAOAE
Equity Capital Advisory (Private Equity Placements, Growth Capital)
SECONDARYBPAHAOAG
Corporate Development & Strategic Partnerships Advisory (JVs, Alliances, Carve-outs)
SECONDARYBPAHADAG
Capital Raising Advisory (Debt/Equity/Private Capital)
SECONDARYFSAEAGAE
Corporate Finance Advisory (Strategic Finance, Capital Structure & Recaps)
NAICS code2 codes
  • Investment Banking and Securities Intermediation523150
  • Investment Banking and Securities Intermediation52315
SIC code2 codes
  • Security Brokers, Dealers & Flotation Companies6211
  • Investment Advice6282
Product category
Investment Banking and Strategic Advisory
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Success Fees on Advisory Transactions
TypeTransaction Fee
Description

Primary revenue derived from pre-determined percentage of fees paid by issuers upon successful transaction completion. Works with multiple issuers and fees vary by each engagement.

outcomecapital.com
2Private Placement Securities
TypeSubscription Recurring
Description

Acts as broker-dealer offering private placement of securities to qualified institutional investors on behalf of issuers raising capital through private placements exempt from registration.

outcomecapital.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details1 tier
1Success fee model based on transaction value
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Fees paid by Issuer upon successful transaction close, not directly by investors. Fee percentages are pre-determined per engagement.

outcomecapital.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Outcome Capital provides investment banking and strategic advisory services to middle-market growth companies in the life sciences and healthcare sectors. Its core offerings include M&A advisory, capital raising (equity financing and private placements), strategic advisory, and financial advisory, delivered through a scientist-banker model that pairs PhD-trained professionals with deep sector expertise. The firm is an SEC-registered broker-dealer and FINRA member, enabling it to act as exclusive strategic and financial advisor on transactions such as mergers, acquisitions, licensing deals, and growth equity financings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Value added 10x greater than value invested in services per client testimonial
+1 more record
Product overview1 text field

Outcome Capital offers a unified advisory platform combining investment banking and strategic advisory services for middle-market growth companies in the life sciences and healthcare sectors. The firm operates two core service lines: Investment Banking (encompassing M&A advisory, capital raising, value creation, and value realization) and Advisory (including strategic and financial advisory). These services are delivered through specialized industry practices covering Life Sciences (Biotech, Diagnostics, Medical Devices, Pharmaceuticals) and Healthcare (Healthcare IT, Digital Health, Pharma Services, Healthcare Services), with dedicated offerings like the Pharmacy and Related Services Advisory Board and Healthcare Services Practice providing sector-specific strategic expertise. The firm positions itself as a strategic partner helping clients move innovations from development through commercialization.

Product and service10 records
1Investment Banking
CategoryCore Service
Description

Strategic investment banking services including M&A advisory, capital raising, value creation, and value realization for middle-market growth companies in life sciences and healthcare.

2Strategic Advisory
CategoryAdvisory Service
Description

Strategic advisory services focused on helping companies navigate market dynamics, optimize positioning, and develop market-driven strategies for M&A and financing transactions.

3Financial Advisory
CategoryAdvisory Service
Description

Financial advisory services including transaction structuring, valuation analysis, and financing support for life sciences and healthcare transactions.

4Life Sciences Practice
CategoryIndustry Practice
Description

Advisory and investment banking services serving the Biotech, Diagnostics, Medical Devices, and Pharmaceutical Industries.

5Healthcare Practice
CategoryIndustry Practice
Description

Advisory and investment banking services serving Healthcare IT, Digital Health, Pharma Services, and Healthcare Services industries.

6Healthcare Services Practice
CategoryPractice Area
Description

Dedicated practice area expanding strategic advisory and investment banking capabilities specifically focused on the Healthcare Services sector.

7Pharmacy and Related Services Advisory Board
CategoryAdvisory Board
Description

Advisory board providing strategic expertise for clients navigating changes in the pharmacy sector, focusing on innovation, regulation, and technology, and helping clients capitalize on market disruptions and technological advances.

8Value Creation
CategoryInvestment Banking Sub-service
Description

Investment banking value creation services within the Investment Banking service line, focused on enhancing company value prior to transaction events.

9Value Realization
CategoryInvestment Banking Sub-service
Description

Investment banking value realization services within the Investment Banking service line, focused on executing liquidity events including M&A exits, IPOs, and strategic transactions.

10Private Placement of Securities
CategoryBroker-Dealer Service
Description

Broker-dealer service offering private placement of securities to qualified institutional investors on behalf of issuers raising capital through private placements exempt from registration.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Piper Sandler operates one of the most active healthcare and life sciences investment banking practices among US middle-market banks, providing M&A advisory, capital raising, and equity research to biotech, medtech, and healthcare services companies — directly comparable to Outcome Capital's core offering and middle-market focus.

TypeDirect peer
Description

H.C. Wainwright is a boutique investment bank specializing in healthcare and life sciences with deep biotech equity placement and advisory capabilities. Its biotech-focused DNA, broker-dealer placement activity, and middle-market client base make it a close comparable to Outcome Capital.

TypeDirect peer
Description

Jefferies runs a large global healthcare investment banking franchise covering biotech, medtech, and pharma services with M&A and capital markets capabilities. Its middle-market healthcare advisory footprint and placement agent activity overlap directly with Outcome Capital's service mix.

TypeDirect peer
Description

Oppenheimer's Healthcare Investment Banking group provides M&A advisory and capital raising for life sciences and healthcare services companies across the middle market — a comparable boutique-style franchise competing for the same issuer mandates as Outcome Capital.

TypeDirect peer
Description

Canaccord Genuity's healthcare investment banking group focuses on growth-stage biotech, medtech, and digital health M&A and equity financings. Its niche specialization and middle-market life sciences focus closely mirror Outcome Capital's positioning.

TypeDirect peer
Description

Guggenheim Securities operates a healthcare investment banking franchise advising on M&A, equity, and debt financings for life sciences companies — directly comparable in client base, deal types, and middle-to-upper-middle market positioning to Outcome Capital.

TypeDirect peer
Description

Wedbush's Healthcare Investment Banking group covers biotech, medtech, and digital health M&A and capital raising. Its boutique orientation and life sciences focus align closely with Outcome Capital's service model and target issuer base.

TypeDirect peer
Description

SVB Securities built a healthcare-focused investment banking franchise advising biotech, medtech, and healthcare technology clients on IPOs, follow-ons, and M&A. Its vertical specialization and growth-stage client base overlap with Outcome Capital's middle-market life sciences focus.

9Raymond James (Healthcare IB)
TypeDirect peer
Description

Raymond James' Healthcare Investment Banking group advises on M&A, equity, and debt financings for life sciences, medical devices, and healthcare services companies. Its middle-market focus and broad life sciences coverage make it a relevant comparable.

TypeDirect peer
Description

Ladenburg Thalmann operates a healthcare and life sciences investment banking practice focused on middle-market advisory and capital raising. Its boutique scale and life sciences vertical emphasis closely parallel Outcome Capital's profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment10 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Outcome Capital

Investment Banking and Strategic Advisoryoutcomecapital.com

Outcome Capital is a privately held Boston-based investment banking and strategic advisory firm serving middle-market growth companies in life sciences and healthcare, providing M&A advisory, capital raising, and strategic advisory through a scientist-banker team with PhD-trained Managing Directors and Big Pharma operating experience.

What Outcome Capital does

Outcome Capital, LLC is a privately held investment banking and strategic advisory firm headquartered in Boston, Massachusetts, with a secondary office in Charlotte, North Carolina. Founded around 1998-2000 and registered with the SEC as a broker-dealer and FINRA/SIPC member, the firm operates as an affiliate of Outcome Holdings, LLC and focuses exclusively on middle-market growth companies in the life sciences and healthcare sectors, spanning biotech, diagnostics, medical devices, pharmaceuticals, healthcare IT, digital health, pharma services, and healthcare services. Its service platform combines investment banking (M&A advisory, capital raising, value creation, value realization) with strategic and financial advisory, delivered through dedicated industry practices and supported by content such as the Life Sciences Pulse monthly newsletter.

The firm differentiates itself through a scientist-banker model: most Managing Directors and Vice Presidents hold PhDs or CFA credentials with prior operating roles at major pharmaceutical and medical device companies including Novartis, Pfizer, Bayer, Johnson & Johnson, Schering-Plough, and Becton-Dickinson. Notable closed transactions include the $175M Propella Therapeutics acquisition by Astellas Pharma, the $120M GenePOC acquisition by Meridian Bioscience, a $32M Elios Vision growth equity financing, the ZIEN Medical/Averra Holdings merger, and the RealizedCare/XRHealth acquisition, among others spanning 2016-2025.

Outcome Capital earns revenue primarily through success fees paid by issuers upon closing of M&A and capital raising mandates, supplemented by fees from private placement of securities to qualified institutional investors. Pricing is not publicly disclosed; fee percentages are pre-determined per engagement and vary by transaction. The firm has no productized software, AI/ML, or technology platform; its offering is advisory labor and relationship-based deal execution, with recent expansion in 2025-2026 via the Healthcare Services Practice, the Pharmacy and Related Services Advisory Board, and an ophthalmology practice led by a new senior hire.

Outcome Capital firmographics

Firmographics
Name
Outcome Capital
Legal name
Outcome Capital, LLC
Website
https://outcomecapital.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
Outcome Capital is a privately held Boston-based investment banking and strategic advisory firm serving middle-market growth companies in life sciences and healthcare, providing M&A advisory, capital raising, and strategic advisory through a scientist-banker team with PhD-trained Managing Directors and Big Pharma operating experience.
Ownership category
akta.pro rank

Outcome Capital industry classification

Industry
Product category
Investment Banking and Strategic Advisory
NAICS
Investment Banking and Securities Intermediation (523150), Investment Banking and Securities Intermediation (52315)
SIC
Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)
akta.pro industry
PRIMARYBPAHADAB
Corporate Finance & Capital Advisory
SECONDARYBPAHAOAE
Equity Capital Advisory (Private Equity Placements, Growth Capital)
SECONDARYBPAHAOAG
Corporate Development & Strategic Partnerships Advisory (JVs, Alliances, Carve-outs)
SECONDARYBPAHADAG
Capital Raising Advisory (Debt/Equity/Private Capital)
SECONDARYFSAEAGAE
Corporate Finance Advisory (Strategic Finance, Capital Structure & Recaps)

Keywords

  • Life sciences investment banking
  • Healthcare strategic advisory
  • Mergers and acquisitions advisory
  • Capital raising services
  • Middle market advisory

Where Outcome Capital is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Outcome Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Success Fees on Advisory Transactions: Primary revenue derived from pre-determined percentage of fees paid by issuers upon successful transaction completion. Works with multiple issuers and fees vary by each engagement.
  2. Private Placement Securities: Acts as broker-dealer offering private placement of securities to qualified institutional investors on behalf of issuers raising capital through private placements exempt from registration.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goSuccess fee model based on transaction value

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Outcome Capital product offering

Product offering

Core offering

Outcome Capital provides investment banking and strategic advisory services to middle-market growth companies in the life sciences and healthcare sectors. Its core offerings include M&A advisory, capital raising (equity financing and private placements), strategic advisory, and financial advisory, delivered through a scientist-banker model that pairs PhD-trained professionals with deep sector expertise. The firm is an SEC-registered broker-dealer and FINRA member, enabling it to act as exclusive strategic and financial advisor on transactions such as mergers, acquisitions, licensing deals, and growth equity financings.

Product overview

Outcome Capital offers a unified advisory platform combining investment banking and strategic advisory services for middle-market growth companies in the life sciences and healthcare sectors. The firm operates two core service lines: Investment Banking (encompassing M&A advisory, capital raising, value creation, and value realization) and Advisory (including strategic and financial advisory). These services are delivered through specialized industry practices covering Life Sciences (Biotech, Diagnostics, Medical Devices, Pharmaceuticals) and Healthcare (Healthcare IT, Digital Health, Pharma Services, Healthcare Services), with dedicated offerings like the Pharmacy and Related Services Advisory Board and Healthcare Services Practice providing sector-specific strategic expertise. The firm positions itself as a strategic partner helping clients move innovations from development through commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

  • Investment Banking Strategic investment banking services including M&A advisory, capital raising, value creation, and value realization for middle-market growth companies in life sciences and healthcare.
  • Strategic Advisory Strategic advisory services focused on helping companies navigate market dynamics, optimize positioning, and develop market-driven strategies for M&A and financing transactions.
  • Financial Advisory Financial advisory services including transaction structuring, valuation analysis, and financing support for life sciences and healthcare transactions.
  • Life Sciences Practice Advisory and investment banking services serving the Biotech, Diagnostics, Medical Devices, and Pharmaceutical Industries.
  • Healthcare Practice Advisory and investment banking services serving Healthcare IT, Digital Health, Pharma Services, and Healthcare Services industries.
  • Healthcare Services Practice Dedicated practice area expanding strategic advisory and investment banking capabilities specifically focused on the Healthcare Services sector.
  • Pharmacy and Related Services Advisory Board Advisory board providing strategic expertise for clients navigating changes in the pharmacy sector, focusing on innovation, regulation, and technology, and helping clients capitalize on market disruptions and technological advances.
  • Value Creation Investment banking value creation services within the Investment Banking service line, focused on enhancing company value prior to transaction events.
  • Value Realization Investment banking value realization services within the Investment Banking service line, focused on executing liquidity events including M&A exits, IPOs, and strategic transactions.
  • Private Placement of Securities Broker-dealer service offering private placement of securities to qualified institutional investors on behalf of issuers raising capital through private placements exempt from registration.

Quantifiable outcome

  • Value added 10x greater than value invested in services per client testimonial
  • +1 more outcomes

Companies that use Outcome Capital

Customer profile

Named customers14 records

Segments3 records

Ideal customer profiles2 records

Outcome Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Outcome Capital partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Outcome Capital competitors and assessment

Company assessment

Direct peers

  • Piper Sandler: Piper Sandler operates one of the most active healthcare and life sciences investment banking practices among US middle-market banks, providing M&A advisory, capital raising, and equity research to biotech, medtech, and healthcare services companies — directly comparable to Outcome Capital's core offering and middle-market focus.
  • H.C. Wainwright & Co. H.C. Wainwright is a boutique investment bank specializing in healthcare and life sciences with deep biotech equity placement and advisory capabilities. Its biotech-focused DNA, broker-dealer placement activity, and middle-market client base make it a close comparable to Outcome Capital.
  • Jefferies (Healthcare Group): Jefferies runs a large global healthcare investment banking franchise covering biotech, medtech, and pharma services with M&A and capital markets capabilities. Its middle-market healthcare advisory footprint and placement agent activity overlap directly with Outcome Capital's service mix.
  • Oppenheimer & Co. (Healthcare): Oppenheimer's Healthcare Investment Banking group provides M&A advisory and capital raising for life sciences and healthcare services companies across the middle market — a comparable boutique-style franchise competing for the same issuer mandates as Outcome Capital.
  • Canaccord Genuity (Healthcare): Canaccord Genuity's healthcare investment banking group focuses on growth-stage biotech, medtech, and digital health M&A and equity financings. Its niche specialization and middle-market life sciences focus closely mirror Outcome Capital's positioning.
  • Guggenheim Partners (Healthcare IB): Guggenheim Securities operates a healthcare investment banking franchise advising on M&A, equity, and debt financings for life sciences companies — directly comparable in client base, deal types, and middle-to-upper-middle market positioning to Outcome Capital.
  • Wedbush Securities: Wedbush's Healthcare Investment Banking group covers biotech, medtech, and digital health M&A and capital raising. Its boutique orientation and life sciences focus align closely with Outcome Capital's service model and target issuer base.
  • SVB Securities (Healthcare): SVB Securities built a healthcare-focused investment banking franchise advising biotech, medtech, and healthcare technology clients on IPOs, follow-ons, and M&A. Its vertical specialization and growth-stage client base overlap with Outcome Capital's middle-market life sciences focus.
  • Raymond James (Healthcare IB): Raymond James' Healthcare Investment Banking group advises on M&A, equity, and debt financings for life sciences, medical devices, and healthcare services companies. Its middle-market focus and broad life sciences coverage make it a relevant comparable.
  • Ladenburg Thalmann (Healthcare): Ladenburg Thalmann operates a healthcare and life sciences investment banking practice focused on middle-market advisory and capital raising. Its boutique scale and life sciences vertical emphasis closely parallel Outcome Capital's profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Outcome Capital social profiles

Digital presence

Outcome Capital compliance and trust

Trust signal

Compliance2 records

Outcome Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Outcome Capital leadership team

Management profile

Number of profiles

Profiles20 records

Outcome Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Outcome Capital M&A and investment

M&A and investment

M&A1 record

Investments10 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Outcome Capital

What does Outcome Capital do?

Outcome Capital provides investment banking and strategic advisory services to middle-market growth companies in the life sciences and healthcare sectors. Its core offerings include M&A advisory, capital raising (equity financing and private placements), strategic advisory, and financial advisory, delivered through a scientist-banker model that pairs PhD-trained professionals with deep sector expertise. The firm is an SEC-registered broker-dealer and FINRA member, enabling it to act as exclusive strategic and financial advisor on transactions such as mergers, acquisitions, licensing deals, and growth equity financings.

Is Outcome Capital a public or private company?

Outcome Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Outcome Capital founded?

Outcome Capital was founded in 2000. It employs 11 to 50 people.

Where is Outcome Capital based?

Outcome Capital is headquartered in Boston, United States, in the North America region.

How does Outcome Capital make money?

Two revenue lines are on record. Success Fees on Advisory Transactions are the primary driver. The others are private Placement Securities.

Who are Outcome Capital's main competitors?

Direct peers on record are Piper Sandler, H.C. Wainwright & Co., Jefferies (Healthcare Group), Oppenheimer & Co. (Healthcare), Canaccord Genuity (Healthcare), Guggenheim Partners (Healthcare IB), Wedbush Securities, SVB Securities (Healthcare), Raymond James (Healthcare IB) and Ladenburg Thalmann (Healthcare).

Does Outcome Capital have an API?

No public API is recorded for Outcome Capital.

What industry is Outcome Capital in?

Outcome Capital's product category is Investment Banking and Strategic Advisory. Its primary akta.pro industry code is BPAHADAB, Corporate Finance & Capital Advisory, with a secondary code of BPAHAOAE, Equity Capital Advisory (Private Equity Placements, Growth Capital). Its NAICS code is 523150 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startup ResearcherOutcome Capital Appoints David Feygin as Digital Health and AI HeadOutcome Capital appointed Dr. David Feygin as Managing Director and Head of Digital Health, SaaS and AI. He will lead the firm's practice, advising on strategic transactions, and the move follows rapid AI-digital health convergence. Feygin plans to help founders demonstrate scalable AI business models and assist acquirers in distinguishing real innovation from hype.BioSpaceOutcome Capital Expands Life Science and Healthcare Advisory Capabilities with Addition of Dr. David Feygin to Medical Device, Digital Health and AI PracticesOutcome Capital appointed Dr. David Feygin as Senior Advisor to its Medical Device, Digital Health and AI practices. He brings experience as CEO of ShakeIQ and EnPraxis, and previously led digital and data efforts at Boston Scientific. The appointment expands the firm's advisory capabilities in life sciences and healthcare.citybizOutcome Capital Hires Jaison Ellis as Managing Director to Expand Healthcare Advisory PlatformOutcome Capital, a life sciences and healthcare advisory and investment banking firm, has appointed Jaison Ellis as Managing Director to expand its M&A and strategic advisory platform. Ellis joins from Wells Fargo's healthcare investment banking group where he spent over a decade and brings experience spanning more than $150 billion in completed transactions across biopharmaceuticals, pharma services, and laboratory services. The hire reflects the firm's strategy to attract experienced talent as boutique advisory firms compete with larger banks for middle-market and growth-company mandates in healthcare.Business Wire BlogOutcome Capital Further Bolsters Its Platform with the Addition of Jaison EllisOutcome Capital, a Boston-based life sciences and healthcare advisory and investment banking firm, announced that Jaison Ellis has joined as a Managing Director in Charlotte, NC, expanding the firm's healthcare practices. Ellis brings over $150 billion in transaction experience from previous roles at Wells Fargo, BMO Capital Markets, and Credit Suisse. The firm stated that attracting top talent is central to its strategy-led execution model and continued growth.OutcomecapitalOutcome Capital Launches Dedicated Healthcare Services Practice to Expand Strategic Advisory and Investment Banking CapabilitiesOutcome Capital, LLC announced the launch of its Healthcare Services Practice, expanding the firm’s strategic and transactional advisory capabilities for companies operating in the healthcare services sector. The new practice will be led by Charles Simmons and focus on pharmacy and related services, payor and provider innovation, care delivery transformation, and digital health. This initiative reinforces Outcome Capital’s commitment to providing specialized sector expertise in high-growth segments of the healthcare market.FinancialContent Business PageOutcome Capital Launches the First Dedicated Ophthalmology Practice to Address the World’s Leading Cause of DisabilityOutcome Capital appointed Paul Ryb as Managing Director to lead its first dedicated ophthalmology practice, targeting eye disease as a leading cause of disability. The firm cites vision impairment affecting over 2.2 billion people globally. Ryb will support ophthalmic innovation through venture support, market intelligence, and deal structuring.PR NewswireMaxim Biomedical, Inc. Announces New Minority Investment Partner and Appoints Jonathan Maa as CEOMaxim Biomedical, Inc. announced a new minority investment from CTM Investments and appointed Jonathan Maa as its new Chief Executive Officer. This leadership transition sees Co-Founder Dr. Joe Maa moving to the role of Chief Scientific Officer, while Outcome Capital served as the exclusive advisor for the transaction. The move is intended to support the company's growth in rapid diagnostic test development and manufacturing.GlobeNewswireTFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing OpportunitiesTFF Pharmaceuticals engaged Outcome Capital as a strategic advisor to evaluate corporate partnerships and licensing opportunities. The company highlighted its two lead clinical assets, TFF VORI and TFF TAC, as having significant innovation and commercial potential. Outcome Capital will work with TFF to identify opportunities to realize the full potential value of its Phase 2 assets.YahooTFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing OpportunitiesTFF Pharmaceuticals engaged Outcome Capital as a strategic advisor to evaluate potential corporate partnerships and licensing opportunities. The company highlighted its two lead clinical assets, TFF VORI and TFF TAC, as having significant innovation and commercial potential. Outcome Capital will work with TFF to identify opportunities to realize the full potential value of its Phase 2 assets.GlobeNewswireTFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing OpportunitiesTFF Pharmaceuticals engaged Outcome Capital as a strategic advisor to evaluate corporate partnerships and licensing opportunities. The company highlighted its two lead clinical assets, TFF VORI and TFF TAC, as having significant innovation and commercial potential. Outcome Capital will work with TFF to identify opportunities to realize the full potential value of its Phase 2 assets.